TP53 Gene Mutations, Nuclear p53 Accumulation, Expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) Proteins are not Prognostic Factors in De Novo Glioblastoma Multiforme

[1]  M. Bilsky,et al.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics , 1996, Journal of Neuro-Oncology.

[2]  D. Schiffer,et al.  Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study , 1996, Journal of Neuro-Oncology.

[3]  S. Nakasu,et al.  bcl-2 protein expression in tumors of the central nervous system , 2004, Acta Neuropathologica.

[4]  A. Asai,et al.  Expression level of Bcl-2 determines anti- or proapoptotic function. , 1999, Cancer research.

[5]  V. P. Collins,et al.  Progression as exemplified by human astrocytic tumors. , 1999, Seminars in cancer biology.

[6]  D. Bigner,et al.  Molecular pathogenesis of malignant gliomas. , 1999, Current opinion in oncology.

[7]  M. Israel,et al.  Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells. , 1999, Cancer research.

[8]  M. Israel,et al.  p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. , 1999, International journal of radiation oncology, biology, physics.

[9]  P. Kleihues,et al.  Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.

[10]  M. Israel,et al.  The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Peter,et al.  Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. , 1998, Current opinion in immunology.

[12]  L. Deangelis,et al.  Malignant glioma: Who benefits from adjuvant chemotherapy? , 1998, Annals of neurology.

[13]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[14]  P. Forsyth,et al.  Long-term Glioblastoma Multiforme Survivors: a Population-based Study , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  S. Leenstra,et al.  Genetic sub‐types of human malignant astrocytoma correlate with survival , 1998, International journal of cancer.

[16]  Douglas C. Miller,et al.  bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status , 1997, Acta Neuropathologica.

[17]  T. McDonnell,et al.  Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. , 1997, Journal of the National Cancer Institute.

[18]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[19]  R. Fimmers,et al.  Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. , 1996, Journal of neurosurgery.

[20]  M. J. van de Vijver,et al.  Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. , 1996, British Journal of Cancer.

[21]  H. Moch,et al.  Prognostic significance of Bcl-2 in clinically localized prostate cancer. , 1996, The American journal of pathology.

[22]  G. Baretton,et al.  bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. , 1996, American journal of clinical pathology.

[23]  W. Yung,et al.  Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. , 1996, Cancer research.

[24]  G. Baretton,et al.  Apoptosis and immunohistochemical bcl‐2 expression in colorectal adenomas and carcinomas: Aspects of carcinogenesis and prognostic significance , 1996, Cancer.

[25]  W. Dewey,et al.  p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. , 1996, International journal of radiation oncology, biology, physics.

[26]  Cairncross Jg,et al.  Treatment of malignant glioma in adults , 1995 .

[27]  J. Bruner,et al.  Increased levels of p21WAF1/Cip1 in human brain tumors. , 1995, Oncogene.

[28]  D. Maintz,et al.  Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. , 1995, British Journal of Cancer.

[29]  G. Viale,et al.  Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. , 1995, Human pathology.

[30]  D. Ellison,et al.  Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl‐2 and p53 proteins , 1995, Neuropathology and applied neurobiology.

[31]  H. Takebe,et al.  Changes in Radiation Sensitivity of Human Osteosarcoma Cells after p53 Introduction , 1995, Japanese journal of cancer research : Gann.

[32]  C. Cordon-Cardo,et al.  Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line , 1995, Neurology.

[33]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[34]  D. Louis,et al.  Human gliomas with wild-type p53 express bcl-2. , 1995, Cancer research.

[35]  K. Roemer,et al.  Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Louis,et al.  Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.

[37]  J. Cairncross,et al.  Treatment of malignant glioma in adults. , 1995, Current opinion in neurology.

[38]  J. Cairncross,et al.  p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. , 1994, Journal of the National Cancer Institute.

[39]  John Calvin Reed,et al.  Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.

[40]  R. Fimmers,et al.  TP53 alterations and clinical outcome in low grade astrocytomas , 1994, Genes, chromosomes & cancer.

[41]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[42]  R. McLendon,et al.  Alterations of the TP53 gene in human gliomas. , 1994, Cancer research.

[43]  C J Kemp,et al.  The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. , 1994, Cancer research.

[44]  M. Salcman,et al.  Long-term survival in patients with malignant astrocytoma. , 1994, Neurosurgery.

[45]  D. Louis.  The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.

[46]  D. Lane,et al.  p53 In tumour pathology: Can we trust immunohistochemistry?—revisited! , 1994, The Journal of pathology.

[47]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[48]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[49]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[50]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[51]  M. Prados,et al.  Long-term survival in patients with glioblastoma multiforme. , 1993, Neurosurgery.

[52]  P J Kelly,et al.  Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. , 1993, Journal of neurosurgery.

[53]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[54]  B. Scheithauer,et al.  Histological Classification of Tumours of the Central Nervous System , 1993 .

[55]  B. Scheithauer,et al.  Histological Typing of Tumours of the Central Nervous System , 1993, World Health Organization.

[56]  R. Selker,et al.  Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. , 1992, Surgical neurology.

[57]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[58]  M. Raff,et al.  Social controls on cell survival and cell death , 1992, Nature.

[59]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[60]  N. Vick,et al.  Effects of treatment on long‐term survivors with malignant astrocytomas , 1990, Annals of neurology.

[61]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[62]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Cairncross,et al.  Selection bias in clinical trails of anaplastic glioma , 1989, Annals of neurology.

[64]  L. Salford,et al.  Ten-year survival among patients with supratentorial astrocytomas grade III and IV. , 1988, Journal of neurosurgery.

[65]  L D Lunsford,et al.  Survival after stereotactic biopsy of malignant gliomas. , 1988, Neurosurgery.

[66]  ChB PhD MRCPath T. H. Moss MB.  Tumours of the Nervous System , 1986, Springer London.

[67]  D. Schoenfeld,et al.  Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study , 1983, Cancer.

[68]  D P Byar,et al.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.

[69]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[70]  K. Zulch.  Histologic typing of tumours of the central nervous system , 1979 .

[71]  R Fankhauser,et al.  Tumours of the nervous system. , 1974, Bulletin of the World Health Organization.

[72]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.